Antiplatelet Effect of Losartan and Telmisartan in Patients With Ischemic Stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 16, Issue 5, 2007, Pages 225-231

  Yamada, Koji ^a   Hirayama, Toshikazu ^a   Hasegawa, Yasuhiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ischemic stroke; Losartan; platelet activation; telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CILOSTAZOL; LOSARTAN; PADGEM PROTEIN; TELMISARTAN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; BLOOD PLATELETS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548433512     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2007.07.003     Document Type: Article

References (23)

1. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346 (1995) 1647-1653
2. Omae T., and Ueda K. Hypertension and cerebrovascular disease-the Japanese experience. J Hypertens 6 (1988) 343-349
3. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-pacific region. J Hypertens 21 (2003) 707-716
4. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease, part 1: Prolonged differences in blood pressure; prospective observational studies corrected for the regression dilution bias. Lancet 335 (1990) 765-774
5. UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
6. Gorelick P.B. Stroke prevention therapy beyond antithrombotics: Unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 33 (2002) 862-875
7. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 359 (2002) 995-1003
8. Yamazaki M., Uchiyama S., and Iwata M. Measurement of platelet fibrinogen binding and P-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 104 (2001) 197-205
9. Marquardt L., Ruf A., Mansmann U., et al. Course of platelet activation markers after ischemic stroke. Stroke 33 (2002) 2570-2574
10. Guerra-Cuesta J.I., Monton M., Rodriguez-Feo J.A., et al. Effect of losartan on human platelet activation. J Hypertens 17 (1999) 447-452
11. Nunez A., Gomez J., Zalba L.R., et al. Losartan inhibits in vitro platelet activation: Comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 1 (2000) 175-179
12. Monton M., Jimenez A., Nunez A., et al. Comparative effect of angiotensin II AT-1-type receptor antagonist in vitro on human platelet activation. J Cardiovasc Pharmacol 35 (2000) 906-913
13. Levy P.J., Yunis C., Owen J., et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 86 (2000) 1188-1192
14. Schwemmer M., Sommer O., and Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther 15 (2001) 301-307
15. Kramer C., Sunkomat J., Witte J., et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 90 (2002) 770-776
16. Kalinowski L., Matys T., Chabielska E., et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 40 (2002) 521-527
17. Nomura S., Shouzu A., Omoto S., et al. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 18 (2004) 177-185
18. Ozaki Y., Satoh K., Yatomi Y., et al. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 218 (1994) 284-294
19. Whisnant J.P., Basford J.R., Bernstein E.F., et al. Special report from the National Institute of Neurological Disorders and Stroke: Classification of cerebrovascular disease III. Stroke 21 (1990) 637-676
20. Cherian P., Hankey G.J., Eikelboom J.W., et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 34 (2003) 2132-2137
21. Buczko W., Matys T., Pawlak R., et al. Studies on the antithrombotic action of AT1 receptor antagonists. Med Sci Monit 7 (2001) 600-605
22. Owens P., Kelly L., Nallen R., et al. Comparison of antihypertensive and metabolite effects of losartan and losartan in combination with hydrochlorothiazide-a randomized controlled trial. J Hypertens 18 (2000) 339-345
23. Akdemir R., Ozhan H., Yazici M., et al. In vivo effect of losartan on platelet aggregation in patients with hypertension. Heart Vessels 19 (2004) 167-171